RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
106 hedge funds and large institutions have $815M invested in RAPT Therapeutics in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 24 reducing their positions, and 22 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 24
47% more call options, than puts
Call options by funds: $8.41M | Put options by funds: $5.74M
0.15% less ownership
Funds ownership: 11.34% → 11.19% (-0.15%)
3% less capital invested
Capital invested by funds: $842M → $815M (-$27.2M)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
3% less funds holding
Funds holding: 109 → 106 (-3)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.7M |
| 2 |
PA
Perceptive Advisors
New York
|
+$14.3M |
| 3 |
Morgan Stanley
New York
|
+$13.8M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$12.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
-$82.1M |
| 2 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$13.9M |
| 3 |
VA
VR Adviser
New York
|
-$12.4M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$10.6M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.58M |
RAPT Hedge Fund Activity: Q3 2021 in Review
106 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q3 2021, worth a combined $815M — down 3.2% from $842M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of RAPT and 20 opened new positions — a net loss of 2 holders — while 24 trimmed existing stakes and 51 added.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $37.7M. The largest seller was Column Group, cutting an estimated $82.1M.
- 106 institutional investors held RAPT Therapeutics (RAPT) as of Q3 2021, down from 109 in Q2 2021.
- Funds reported $815M of RAPT Therapeutics stock for Q3 2021, down 3.2% quarter-over-quarter.
- 20 funds opened new RAPT Therapeutics positions in Q3 2021 and 22 closed out, a net change of -2 holders.
- The largest RAPT Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $37.7M added.
- The largest RAPT Therapeutics seller in Q3 2021 was Column Group, an estimated $82.1M sold.
Based on aggregated 13F filings for Q3 2021.